SSSaulo Brito Silva

Saulo Brito Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saulo Brito Silva has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Adilson Aparecido Faccio

    Department of Internal Medicine, Ribeirao Preto Medical School University of Sao Paulo Ribeirao Preto Brazil

    1 shared publication
  • Bruno Rodriguez Pereira

    Hospital Aldenora Bello, São Luis, MA, Brazil

    1 shared publication
  • Carlos Wagner S. Wanderley

    Center for Research in Inflammatory Diseases (CRID) and Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil

    1 shared publication
  • Caroline Sales Figueiredo

    Hospital Sírio-Libanês, São Paulo, Brazil

    1 shared publication
  • Danilo Tadao Wada

    Department of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School University of São Paulo Ribeirão Preto Brazil

    1 shared publication
  • Denize Bodnar

    Centro de Pesquisas Oncológicas—CEPON, Florianópolis, SP, Brazil

    1 shared publication

Latest Publications

  • Open Access

    Biomass burning, PM2.5 peaks, and trends in lung adenocarcinoma diagnoses: an ecological study in São Paulo State, Brazil

    by Saulo Brito Silva, Henrique Goldhart Larssen, Leandro Machado Colli

    Lung adenocarcinoma diagnoses have increased globally despite declining tobacco exposure, raising questions about non-tobacco-related contributors. The role of fine particulate matter (PM2.5) peaks related to biomass burning in shaping population-level lung cancer patterns remains unexplored. An ecological analysis was conducted across the Regional Health Departments of São Paulo State, Brazil, from 2000 to 2023. Histologically confirmed lung cancer cases were obtained from the state cancer registry. Temporal trends in the adenocarcinoma-to-total lung cancer ratio (ATR) were evaluated alongside annual mean and maximum PM2.5 concentrations and wildfire counts derived from satellite data. Among 51,580 lung cancer cases, adenocarcinoma accounted for 36%. Regions with a significant increase in ATR demonstrated annual increases ranging from 0.39 to 0.72%. With the exception of the São Paulo metropolitan area, which showed high mean PM2.5 levels despite low wildfire activity, all other regions with increasing ATR exhibited substantially higher wildfire occurrence (311 vs. 207 annual hotspots; p = 0.049), which strongly correlated with PM2.5 peaks (ρ = 0.928, p = 0.007). Periods of elevated PM2.5 peaks consistently coincided with increased wildfire activity. These findings suggest that biomass-burning-related PM2.5 peaks may be relevant to population-level patterns of lung cancer epidemiology.

  • Open Access

    Rethinking Invasive Mediastinal Staging in the Era of Neoadjuvant Immune‐Checkpoint Inhibitors

    by Saulo Brito Silva, Danilo Tadao Wada, Lycio Umeda Dessotte, Li Siyuan Wada, Adilson Aparecido Faccio, Federico Garcia Cipriano

    Over the past several decades, the management of nonmetastatic nonsmall cell lung cancer (NSCLC) has centered on identifying patients eligible for upfront surgical treatment. This selection has traditionally relied on multidisciplinary assessments of clinical operability and oncologic resectability, with the latter depending primarily on mediastinal lymph node evaluation, a key prognostic factor in determining whether patients should be directed toward upfront surgery or definitive chemoradiotherapy. The recent incorporation of immune checkpoint inhibitors (ICIs) into standard neoadjuvant therapy has transformed this paradigm. By significantly enhancing pathologic response and improving survival across the full spectrum of N2 disease, neoadjuvant ICI therapy is reshaping the prognostic weight traditionally assigned to mediastinal nodal involvement, challenging long‐standing staging practices. Rather than serving primarily to exclude patients from surgery, mediastinal assessment in the immunotherapy era may play a more selective role in baseline risk stratification while also potentially gaining new roles, such as in the evaluation of treatment response and nodal downstaging, which could support broader refinements in clinical decision‐making. This update synthesizes emerging evidence and evolving clinical concepts to re‐examine mediastinal assessment in the immunotherapy era, with implications for clinical decision‐making and future trial design in nonmetastatic NSCLC.

  • Open Access

    Radiotherapy for Brain Metastases Near the End of Life: Characterizing Patients and Tumor Features

    by Saulo Brito Silva, Rafael Balsini Barreto, Fernanda Cristina Gonçalves de Oliveira, Gabriela Schmidt Defende Martin, Ofelia Maria Yukie Takiguchi, Iasmin Alves Chirichela, Mário Henrique Furlanetto Miranda, Denize Bodnar, Luiz Augusto Alves Reis, Gabriel Clemente Brito Pereira, et al.

    PURPOSE: Patients with brain metastases are often referred for brain radiotherapy (BrRT) when exclusive palliative management would be more appropriate. To assess the indication of BrRT during end-of-life (EOL) care and evaluate the characteristics of the patients who underwent the treatment. METHODS: This retrospective study comprised patients from four independent oncology centers who had undergone BrRT for metastases. The variables included were Karnofsky performance status (KPS), primary tumor site, metastatic status, neurologic symptomatic status, the number and size of metastases, posterior fossa or meningeal involvement, type of BrRT, having undergone brain metastasectomy, and the availability of systemic therapies after BrRT. Patients were allocated into three subgroups with ≤30, 31-60, and 61-90 days of survival, and a control group of patients who survived >90 days. RESULTS: A total of 546 patients were included in the study. A KPS of 90 days. CONCLUSION: Considering patients' performance status and whether they are candidates for brain metastasectomy or systemic therapies after BrRT is critical to improving BrRT benefits in scenarios of EOL.


  • Open Access

    Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC

    by Saulo Brito Silva, Carlos Wagner S. Wanderley, José Flavio Gomes Marin, Mariana Petaccia de Macedo, Ellen Caroline Toledo Do Nascimento, Fernanda Frozoni Antonacio, Caroline Sales Figueiredo, Mateus Trinconi Cunha, Fernando Q. Cunha, Gilberto de Castro Junior

    Background: A significant proportion of patients with non-small-cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICIs). Since metabolic reprogramming with increased glycolysis is a hallmark of cancer and is involved in immune evasion, we used 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) to evaluate the baseline glycolytic parameters of patients with advanced NSCLC submitted to ICIs, and assessed their predictive value. Methods: 18F-FDG PET/CT results in the 3 months before ICIs treatment were included. Maximum standardized uptake values, whole metabolic tumor volume (wMTV), and whole-body total lesion glycolysis (wTLG) were evaluated. Cutoff values for high or low glycolytic categories were determined using receiver-operating characteristic curves. Progression-free survival (PFS) and overall survival (OS) were evaluated. Patients with a complete response and a matching group with resistance to ICIs underwent immunohistochemistry analysis. An unsupervised k-means clustering model integrating programmed cell death ligand 1 (PD-L1) expression, glycolytic parameters, and ICIs therapy was performed. Results: In all, 98 patients were included. Lower baseline 18F-FDG PET/CT parameters were associated with responses to ICIs. Patients with low wMTV or wTLG had improved PFS and OS. High wTLG, strong tumor expression of glucose transporter-1, and lack of responses were significantly associated. Patients with low glycolytic parameters benefited from ICIs, regardless of chemotherapy. Conversely, those with high parameters benefited from the addition of chemotherapy. Patients with higher wTLG and lower PD-L1 were associated with progression and worse survival to ICIs monotherapy. Conclusions: Glycolytic metabolic profiles established through baseline 18F-FDG PET/CT are useful biomarkers for evaluating ICI therapy in advanced NSCLC.